Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Um estudo farmacocinético comparativo para avaliar diferentes lotes de fabricação da injeção de BAT1706

28 de setembro de 2026 atualizado por: Bio-Thera Solutions

Um estudo randomizado, duplo-cego, de dose única, de dois braços paralelos para comparar a farmacocinética e a segurança da injeção de BAT1706 de diferentes lotes de fabricação (por novo processo e processo antigo) em indivíduos saudáveis

This is a randomized, double-blind, single-dose, parallel two-arm study to compare the pharmacokinetics, safety, and immunogenicity of BAT1706 Injection from different manufacturing batches (by new process and old process) in healthy male subjects.

Visão geral do estudo

Status

Concluído

Condições

Intervenção / Tratamento

Descrição detalhada

A total of 38 subjects are planned to be enrolled and randomized in a 1: 1 ratio to receive a single intravenous drip of BAT1706 Injection (by old process) or BAT1706 Injection (by new process) at 1 mg/kg body weight.

A 7-day screening period will be set up for this study. Subjects will be admitted to the hospital 1 day pre-dose (Day -1) and discharged after completing relevant observations and assessments 24 h post-dose. After discharge, subjects should return to the hospital for 12 follow-up visits according to the requirements of this study, on Days 3, 4, 5, 8, 11, 15, 22, 29, 36, 43, 57 and 71 post-dose.

Tipo de estudo

Intervencional

Inscrição (Real)

38

Estágio

  • Fase 1

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

    • Anhui
      • Hefei, Anhui, China
        • The Second Affiliated Hospital of Anhui Medical University

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 45 anos (Adulto)

Aceita Voluntários Saudáveis

Sim

Gêneros Elegíveis para o Estudo

Macho

Descrição

Inclusion Criteria:

  1. Healthy male subjects aged between 18 and 45 years with body mass index (BMI) between 18.0 and 28.0 kg/m2 and body weight between 50 and 100 kg (inclusive);
  2. Subjects for whom the results of physical examination, vital signs, 12-lead ECG, and laboratory tests are normal or abnormal without clinical significance;
  3. Subjects who do not smoke, or smoke no more than 5 cigarettes per day for < 10 years;
  4. Subjects who agree to use effective contraception (including but not limited to: hormonal contraception, physical contraception, or abstinence) from the time of signing the informed consent form until 6 months after intravenous drip of the study drug;
  5. Subjects who are willing and able to follow the visits, treatments, laboratory tests, and other relevant procedures specified in this study.

Exclusion Criteria:

  1. Subjects who have previous or current clinically significant gastrointestinal disorder (including diverticulitis, gastric ulcer), renal disorder, liver disorder, cardiovascular disorder, hematological disorder, lung disorder, nervous system disorder, metabolic disorder (including known diabetes mellitus), psychosis, or allergic disease (excluding mild asymptomatic seasonal allergy) at screening/enrollment, and in the opinion of the investigator, are not suitable for participation in this clinical study;
  2. Subjects who have psychiatric disorders, or in the opinion of the investigator, are not suitable for participation in this clinical study (e.g., he is considered unable to understand or follow the relevant requirements of the study, or some of his existing conditions may result in additional risks associated with participation in this study);
  3. Subjects who have previous or current clinically significant allergies (excluding mild asymptomatic seasonal allergy); or subjects who have known or suspected allergy or hypersensitivity to any component of the study drug; or subjects who have known or suspected hypersensitivity to Chinese hamster ovary cell products or other recombinant human or humanized antibodies;
  4. Subjects who have a tendency to haemorrhage or thrombosis, or have a history of non-traumatic haemorrhage with appropriate clinical treatment, or have a history of thrombosis, or have any disease that may increase the risk of haemorrhage or thrombosis (e.g., abnormal coagulation, thrombocytopenia, or INR > 1.5);
  5. Subjects who have any previous malignancy including lymphoma, leukemia, and skin cancer;
  6. Subjects who have abnormal and clinically significant ECG (as judged by the investigator), or corrected QT interval according to Bazett's formula > 470 ms (Bazett's formula: Q-Tc = QT/(R-R)0.5, where R-R represents the interval between two R waves in s);
  7. Subjects who have a history of hypertension, or systolic blood pressure > 145 mmHg or diastolic blood pressure > 95 mmHg at screening/enrollment;
  8. Subjects who have clinically significant chronic or acute infection at screening/enrollment; or have any positive result for HBV surface antigen, HCV antibody, HIV antibody, and treponema pallidum antibody at screening;
  9. Subjects who have previously used Bevacizumab or VEGF-targeting agents;
  10. Subjects who have used any biological product within 3 months prior to enrollment, or have used any monoclonal antibody within 9 months prior to enrollment;
  11. Subjects who have used prescription or over-the-counter drugs within 14 days prior to enrollment, or less than 5 half-lives have passed from the last dose to the dosing day of this study, whichever is longer;
  12. Subjects who have used any Chinese herbal medicine within 14 days prior to enrollment;
  13. Subjects who have participated in other drug clinical trials within 3 months prior to enrollment, or propose to participate in other drug clinical trials during this study;
  14. Subjects who have received live virus vaccine within 12 weeks prior to screening, or plan to receive live virus vaccine during the study;
  15. Subjects who have undergone major injury, surgery, or fracture within 4 weeks prior to enrollment, or propose to undergo surgery during the study;
  16. Subjects who have donated blood or have blood samples > 400 mL collected as subjects within 3 months prior to screening, or plan to donate blood during the study;
  17. Subjects who have a history of alcohol dependence, or have a positive alcohol test result at screening/baseline;
  18. Subjects who have consumed alcoholic beverages within 48 h prior to enrollment;
  19. Subjects who have a history of drug abuse, or have a positive drug abuse test result at screening/baseline;
  20. Subjects who cannot follow the restrictions on smoking, alcohol consumption and concomitant medications for this study during the study;
  21. Subjects who cannot stop high-intensity physical activities from the dosing day of the study drug until 30 days post-dose.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Ciência básica
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Dobro

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: BAT1706(New Process)

Drug: BAT1706

1 mg/kg, the corresponding volume of bulk solution should be drawn according to the actual body weight of the subject, diluted to 100 mL with 0.9% sodium chloride solution, and administered by intravenous drip

1 vial/carton, 400 mg/16 mL/vial

Outros nomes:
  • BAT1706
Comparador Ativo: BAT1706(Old Process)

Drug: BAT1706

1 mg/kg, the corresponding volume of bulk solution should be drawn according to the actual body weight of the subject, diluted to 100 mL with 0.9% sodium chloride solution, and administered by intravenous drip

1 vial/carton, 400 mg/16 mL/vial

Outros nomes:
  • BAT1706

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
AUC0-inf
Prazo: Day1, 2, 3, 4, 5, 8,15, 22, 29, 36, 43, 57, 71

Area under the plasma concentration-time curve from zero to infinity, AUC0-∞ = AUC0-t + Ct/λz

Day1, 2, 3, 4, 5, 8,15, 22, 29, 36, 43, 57, 71
AUC0-t
Prazo: Day1, 2, 3, 4, 5, 8,15, 22, 29, 36, 43, 57, 71

Area under the blood concentration-time curve from time 0 to the last time point at which the concentration can be measured

Day1, 2, 3, 4, 5, 8,15, 22, 29, 36, 43, 57, 71
Cmax
Prazo: Day1, 2, 3, 4, 5, 8,15, 22, 29, 36, 43, 57, 71

Maximum blood concentration

Day1, 2, 3, 4, 5, 8,15, 22, 29, 36, 43, 57, 71
Tmax
Prazo: Day1, 2, 3, 4, 5, 8,15, 22, 29, 36, 43, 57, 71

Observed time to peak concentration

Day1, 2, 3, 4, 5, 8,15, 22, 29, 36, 43, 57, 71
t1/2
Prazo: Day1, 2, 3, 4, 5, 8,15, 22, 29, 36, 43, 57, 71

Elimination half-life t1/2 = 0.693/λz

Day1, 2, 3, 4, 5, 8,15, 22, 29, 36, 43, 57, 71

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Adverse events
Prazo: Day1, 2, 3, 4, 5, 8,15, 22, 29, 36, 43, 57, 71

AE and SAE

Day1, 2, 3, 4, 5, 8,15, 22, 29, 36, 43, 57, 71
Immunogenicity
Prazo: Day1, 2, 3, 4, 5, 8,15, 22, 29, 36, 43, 57, 71

Anti-drug antibody (ADA) positivity, ADA titer and neutralizing antibody (NAb) positivity for ADA.

Day1, 2, 3, 4, 5, 8,15, 22, 29, 36, 43, 57, 71

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Investigadores

  • Investigador principal: Wei Hu, Ph.D, The Second Hospital of Anhui Medical University

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

15 de junho de 2023

Conclusão Primária (Real)

21 de setembro de 2023

Conclusão do estudo (Real)

3 de janeiro de 2024

Datas de inscrição no estudo

Enviado pela primeira vez

28 de abril de 2023

Enviado pela primeira vez que atendeu aos critérios de CQ

9 de maio de 2023

Primeira postagem (Real)

19 de maio de 2023

Atualizações de registro de estudo

Última Atualização Postada (Real)

1 de outubro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

28 de setembro de 2026

Última verificação

1 de setembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • BAT-1706-004-CR

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

produto fabricado e exportado dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever